At the recent European Congress of Rheumatology (EULAR) meeting in London, researchers from Antegene Corp. Ltd. presented the preclinical characterization of ATG-207, an αCD3-TGF-β bifunctional fusion protein, in models of T-cell-driven autoimmune disease.

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by dysregulation in humoral immunity and sustained activation of B cells and autoantibody release, where BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand) play crucial roles in B-cell differentiation and survival. Genescience Pharmaceutical Co. Ltd. has released data for its dual BAFF and APRIL inhibitor Gensci-136 for the treatment of SLE.

If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s biotechnology sector, it was that the industry’s center of gravity is shifting. While Chinese companies once relied heavily on PD-1 antibodies and licensing deals to gain international visibility, this year’s oral presentations showcased a broader innovation base.

About 90% of brain metastases are often limited therapeutically speaking due to the impermeable blood-brain barrier (BBB). Nanocarry Therapeutics Ltd. has presented AxS007, a novel insulin-mediated nanocarrier that delivers multiple copies of trastuzumab and pertuzumab across the BBB, using native insulin as a brain transporter and increasing brain exposure.

The University of Texas MD Anderson Cancer Center reported findings from studies of CBT-001-2334, a radionuclide peptide targeting carbonic anhydrase IX (CAIX/CA9) designed for diagnostic gallium labeling and downstream therapeutic isotope pairing. It features a DOTA chelator for use in theranostic applications through chelating either diagnostic or therapeutic radionuclides. Because it has limited expression in normal tissue, CAIX is an attractive target in clear cell renal cell carcinoma (ccRCC).

17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH) progression, where HSD17B13 exacerbates hepatic lipid metabolism, while CIDEB mainly mediates lipid droplet dynamics and storage. In this context, Frontier Biotechnologies Inc. has presented data on FB-7033, a bispecific siRNA approach targeting both HSD17B13 and CIDEB for the management of MASH.

Neurotensin receptor 1 (NTSR1) is overexpressed in several aggressive solid tumors, including colorectal and pancreatic cancer, making it a promising therapeutic target. SKL-35501 is a novel 225Ac-labeled radiopharmaceutical developed by SK Biopharmaceuticals Co. Ltd. that targets NTSR1 for α-particle therapy.

At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data on ATNM-400 in models of non-small-cell lung cancer (NSCLC).

Oppenheimer analyst Jay Olson trumpeted “a new era” in pancreatic ductal adenocarcinoma (PDAC) after Revolution Medicines Inc.’s data splash with daraxonrasib at the American Society of Clinical Oncology meeting in Chicago – but he wasn’t talking about only that company. Combined with other recent updates in the space, the phase III data from Redwood City, Calif.-based Revolution is providing investors as well as patients with renewed hope in notoriously difficult-to-treat PDAC.

Transforming growth factor-β-activated kinase 1 (TAK1) is a crucial central signaling molecule of hepatic cell death, inflammation and fibrogenesis through NF-κB and MAPK in metabolic dysfunction-associated steatotic liver disease (MASLD). Its pharmacological inhibition using the TAK1 inhibitor HS-276 was tested in vivo in a murine model of diet-induced MASLD.